Evidence map›Paper›PMID 24806343›Full record

ReviewInternational journal of molecular sciences2014

Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Yahui Liu, Hong Qing, Yulin Deng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yahui LiuSchool of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China. liuyahui2049@163.com.
Hong QingSchool of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China. hqing@bit.edu.cn.
Yulin DengSchool of Life Science, Beijing Institute of Technology, No. 5 Zhongguancun South Street, Haidian District, Beijing 100081, China. deng@bit.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a common chronic and destructive disease. The early diagnosis of AD is difficult, thus the need for clinically applicable biomarkers development is growing rapidly. There are many methods to biomarker discovery and identification. In this review, we aim to summarize Mass spectrometry (MS)-based proteomics studies on AD and discuss thoroughly the methods to identify candidate biomarkers in cerebrospinal fluid (CSF) and blood. This review will also discuss the potential research areas on biomarkers.

Indexed as

Alzheimer DiseaseAnimalsBiomarkersBlood ProteinsCerebrospinal Fluid ProteinsHumansMass SpectrometryProteinsProteomicsBiomarkersBlood ProteinsCerebrospinal Fluid ProteinsProteins

Identifiers

PMID24806343
PMCPMC4057708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.